An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary
Veracyte (NASDAQ: VCYT) announced the immediate appointment of Dr. Eliav Barr to its board of directors. Dr. Barr brings extensive biopharmaceutical experience, particularly in global clinical development, which is expected to enhance Veracyte's strategic initiatives, especially in immuno-oncology. CEO Marc Stapley emphasized the potential for improved patient outcomes through this new leadership. Dr. Barr previously held high-level positions at Merck, overseeing critical therapeutic areas and leading the development of key vaccines. Veracyte aims to leverage his expertise to expand biopharmaceutical partnerships.
Positive
Appointment of Dr. Eliav Barr expected to enhance strategic initiatives in biopharmaceutical partnerships.
Dr. Barr's extensive experience in global clinical development will aid in achieving improved patient outcomes.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.
“We are thrilled to welcome Eliav Barr to our board,” said Marc Stapley, Veracyte’s chief executive officer. “Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology.”
Dr. Barr has built his distinguished career at Merck Research Laboratories (MRL), a division of Merck & Co., Inc., a multinational pharmaceutical company, where he has served as Head of Global Clinical Development and Chief Medical Officer since April 2022. In this role, he oversees development programs for pipeline and in-line products in the Cardiovascular, Diabetes/Endocrine/Metabolism, Immunology, Neurology, Oncology, Psychiatry, Respiratory, and Vaccines/Infectious Diseases therapeutic areas. He is also the Chairperson of the Late Development Review Committee, the governance committee that oversees such pipeline. Dr. Barr has held numerous leadership positions within MRL since joining the company in 1995, including serving as Senior Vice President, Global Medical and Scientific Affairs from 2018 to 2022. Notably, he led the development of Merck’s human papillomavirus (HPV) vaccines, which have become key tools in the global effort to reduce the burden of certain cancers and diseases caused by HPV. Prior to joining Merck, Dr. Barr pursued post-doctoral training at the University of Michigan and was on faculty at the University of Chicago. Dr. Barr earned his Doctor of Medicine degree from Jefferson Medical College of Thomas Jefferson University and completed an Internal Medicine residency and Cardiology Fellowship at Johns Hopkins.
“Veracyte is a leader in providing high-value diagnostic tests that help physicians make more informed diagnostic and treatment decisions for their patients,” said Dr. Barr. “I am excited to join Veracyte’s board of directors and help guide the company as it executes on its bold, strategic global vision.”
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. In addition to making our tests available in the United States through our central laboratories, our exclusive license to our best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests, assays, biopharma business opportunities and immuno-oncology offerings. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective,” “potential” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the appointment of Eliav Barr, M.D., to our board of directors may help us achieve our ambition of improving outcomes for patients all over the world. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on February 28, 2022, and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte and the Veracyte logo are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.
